Clinical trials
Recurrent or Metastatic Nasopharyngeal Carcinoma clinical trials
Below are recruiting recurrent or metastatic nasopharyngeal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 2,388 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06886516RecruitingEarly Phase 1
Blood thinner study for cancer patients with low platelets
This study tests if the blood thinner apixaban is safe and effective for cancer patients who have low platelets and a recent blood clot. It may offer a treatment option for those who cannot take standard blood thinners.
Boston, MassachusettsAges 18 years+ - NCT06888063RecruitingPhase 2
Chemo pump into the liver for bile duct cancer that can be surgically removed
This trial tests whether giving extra chemotherapy directly to the liver through a small pump (called HAIP) before or after surgery can improve outcomes for patients with bile duct cancer inside the liver. It is for patients whose cancer is considered removable by surgery.
Rotterdam, South HollandAges 18 years+ - NCT06888921RecruitingPhase 1/Phase 2
COM701 for platinum-sensitive ovarian cancer
This study tests a new drug, COM701, for people with ovarian cancer that came back after treatment but still responds to platinum-based chemotherapy. It aims to see if COM701 is safe and effective for patients who have already tried several treatments.
Augusta, GeorgiaAges 18 years+ - NCT06893380Recruiting
Drug combo plus immunotherapy for advanced bile duct cancer
This study tests a combination of three drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy (tislelizumab) for people with advanced biliary tract cancer who haven't had treatment yet. The goal is to see if this cocktail shrinks tumors better than standard care.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT06898398Recruiting
TACE before surgery for large liver cancer
This trial combines a procedure called TACE (which blocks the blood supply to the tumor) with surgery to remove a large liver tumor. It is for people newly diagnosed with a large liver cancer that hasn't spread and can be completely removed with surgery.
Beijing, Beijing MunicipalityAges 18–75 - NCT06899854Recruiting
Collecting blood and tissue from patients with liver cancer
This study collects blood and tumor tissue samples from people with primary liver cancer who are starting their first treatment (systemic therapy or surgery). The samples help researchers learn more about these cancers and how to improve future treatments.
Pavia, PaviaAges 18–90 - NCT06902350RecruitingPhase 1
Experimental drug CS231295 for advanced solid tumors
This trial tests an experimental drug called CS231295 for people with advanced solid tumors that have not responded to standard treatments. The purpose is to study safety and find out if the drug can shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06903325Recruiting
Monitoring DNA markers in blood to predict colorectal cancer return after surgery
This study tests if a simple blood test can detect early signs of colorectal cancer coming back after surgery to remove cancer spread in the abdomen. It may help patients avoid unnecessary treatments and catch recurrence sooner.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06904196RecruitingPhase 2
Lenvatinib with or without internal radiation for TACE-resistant liver cancer
This trial compares two treatments for liver cancer (HCC) that has stopped responding to TACE. One group gets lenvatinib (a targeted therapy pill) plus SIRT (internal radiation beads placed in the liver), and the other gets lenvatinib alone. The goal is to see which combination works better.
Guangzhou, GuangdongAges 18–75 - NCT06904183RecruitingPhase 2
Study of lenvatinib, sintilimab, and DEB-TACE with or without HAIC for large liver cancer with portal vein tumor thrombus
This trial tests a combination of two drugs (lenvatinib and sintilimab) plus a liver-directed treatment (DEB-TACE) with or without another liver treatment (HAIC) for people with large liver cancer (over 7 cm) that has spread into the main blood vessel of the liver. The goal is to see if adding HAIC helps shrink the cancer more effectively.
Guangzhou, GuangdongAges 18–75 - NCT06905054RecruitingPhase 2
Preventing PSC recurrence after liver transplant
This trial tests whether fenofibrate can prevent primary sclerosing cholangitis (PSC) from coming back after a liver transplant. It is for adults who had a liver transplant for PSC between 1 and 7 years ago and have certain risk factors.
Scottsdale, ArizonaAges 18–75 - NCT06915454Recruiting
Better imaging during cancer surgery
This trial tests a high-resolution PET-CT scan done during surgery to help surgeons see exactly where the cancer ends. It may help make sure all cancer is removed while saving healthy tissue.
Nashville, TennesseeAges 18 years+ - NCT06922591RecruitingPhase 1/Phase 2
TNG462 for pancreatic and lung cancer with MTAP loss
This trial tests a new drug called TNG462, alone or combined with other drugs, for people with advanced pancreatic or non-small cell lung cancer whose tumors have a specific genetic change (loss of MTAP and a RAS mutation). It aims to see if TNG462 is safe and works better than current treatments.
Scottsdale, ArizonaAges 18 years+ - NCT06923826RecruitingPhase 2
Study of sacituzumab govitecan for advanced salivary gland and thyroid cancers
This trial tests a drug called sacituzumab govitecan in people with advanced salivary gland cancer or thyroid cancer that has spread or cannot be removed. The goal is to see if the drug can help shrink or slow down the cancer.
SingaporeAges 21 years+ - NCT06925061RecruitingPhase 2
Testing EXL01 to prevent Crohn's disease return after surgery
This study tests a new oral treatment called EXL01 to see if it can prevent Crohn's disease from coming back after surgery to remove part of the small and large intestine. It may be an option if you are not planning to use strong immune-suppressing drugs (except anti-TNF) in the next 6 months.
Clermont-FerrandAges 18 years+ - NCT06926374Recruiting
Robotic surgery for gastrointestinal and urologic conditions
This trial tests a new robotic surgery system for common operations on the colon, rectum, prostate, kidney, bladder, stomach, esophagus, gallbladder, and hiatal hernia. It may offer a less invasive option for patients who need surgery for these conditions.
Hong KongAges 18–80 - NCT06941363Recruiting
Salvage radiotherapy for prostate cancer recurrence after surgery
This study tests a very short course of radiation given after prostate surgery, specifically for men whose PSA is rising again. The goal is to see if this approach can safely control the cancer.
Monza, ItalyAges 18–90 - NCT06943820RecruitingPhase 1/Phase 2
AK129 combination therapy for advanced solid tumors
This trial tests a new combination of drugs (including AK129) for people with advanced solid tumors, specifically lung cancer, head and neck cancer, or colorectal cancer. It is for those who have already tried a platinum chemo and a PD-1/PD-L1 drug but their cancer got worse.
Shenyang, LiaoningAges 18–75 - NCT06948786RecruitingPhase 2
Pirtobrutinib and Mosunetuzumab for relapsed follicular lymphoma
This trial tests two new drugs, pirtobrutinib and mosunetuzumab, for people with follicular lymphoma that has come back or not responded to earlier treatments. The goal is to see if this combination can help control the cancer.
Seattle, WashingtonAges 18 years+ - NCT06952868RecruitingPhase 2
BNCT for recurrent head and neck cancer
This trial tests a special type of radiation therapy called BNCT (boron neutron capture therapy) for head and neck cancers that have come back and cannot be removed by surgery. It may be an option for patients who have already had radiation and cannot receive standard chemotherapy.
TaichungAges 18–80 - NCT06953999RecruitingPhase 3
Testing immunotherapy plus chemo for metastatic pancreatic cancer
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
Harbin, HeilongjiangAges 18–75 - NCT06954480RecruitingPhase 2
Two drugs vs one for PDL1-negative breast cancer
This trial tests a new combination of two drugs (datopotamab deruxtecan plus durvalumab) against one drug alone (datopotamab deruxtecan) for people with PDL1-negative, triple-negative breast cancer that has spread. The goal is to see if the combination works better.
LondonAges 18 years+ - NCT06954610Recruiting
Heart Check for Stroke Risk in Atrial Fibrillation
This trial uses heart imaging to better understand stroke risk in people with atrial fibrillation (an irregular heartbeat). It may help doctors decide on the best treatment to prevent another stroke.
BernAges 18 years+ - NCT06954961RecruitingPhase 3
Study of D-0502 for ER+ HER2- advanced breast cancer
This trial tests an oral drug called D-0502 for people with a specific type of advanced breast cancer (ER-positive, HER2-negative). It is for those whose cancer has returned or worsened after hormone therapy, and it may be an option before trying more chemotherapy.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Recurrent or Metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic nasopharyngeal carcinoma?
- Yes. Clin2 currently lists 2,388 recruiting recurrent or metastatic nasopharyngeal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic nasopharyngeal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic nasopharyngeal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Recurrent Nasopharyngeal Carcinoma
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Nasopharyngeal Carcinoma
- Metastatic Nasopharyngeal Squamous Cell Carcinoma
- Recurrent Nasopharyngeal Squamous Cell Carcinoma
- Nasopharyngeal Carcinoma
- Metastatic Renal Cell Carcinoma
- Nasopharyngeal Carcinoma (NPC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.